Measure Name: Annual Monitoring of Anticonvulsant, Carbamazepine
Rule Description:
1) The percentage of patients 18 years and older who received at least 180 days of carbamazepine therapy and had at least one therapeutic monitoring event during the measurement year.
2) The percentage of patients 18 years and older who received at least 180 days of phenobarbital therapy and had at least one therapeutic monitoring event during the measurement year.
3) The percentage of patients 18 years and older who received at least 180 days of phenytoin therapy and had at least one therapeutic monitoring event during the measurement year.
4) The percentage of patients 18 years and older who received at least 180 days of valproic acid therapy and had at least one therapeutic monitoring event during the measurement year.
General Criteria Summary
1. Continuous enrollment: 1year
2. Anchor date: 31st December of the measurement year
3. Gaps in enrollment: One 45-day gap allowed in each year of continuous enrollment
4. Medical coverage: Yes
5. Drug coverage: Yes
6. Attribution time frame: 1 year
7. Exclusions apply: Yes
8. Age range: 18 years and older
Note: Four separate denominator measures are being created because each subset used in a measure has to reference a specific rule. It would be confusing to customers if we had measures that referred to rules that seemed unrelated. Therefore, there are separate subset and measure specifications for each Annual Monitoring denominator, even though the calculation of each denominator is exactly the same.
Denominator Description: All patients aged 18 years and older who received at least 180 treatment days of ambulatory anticonvulsant medication therapy during the measurement year
Inclusion Criteria: Patients aged 18 years and older as of the end of the measurement year who received at least 180 treatment days of ambulatory anticonvulsant medication therapy during the measurement year. The four types of anticonvulsants checked are carbamazepine, phenobarbital, phenytoin, and valproic acid.
CPT Description: Drug serum concentration for carbamazepine
80156 Carbamazepine; total
80157 Carbamazepine; free
LOINC
Description: Drug serum concentration for carbamazepine
3432-2 Drug serum concentration for carbamazepine
3433-0 Drug serum concentration for carbamazepine
9415-1 Drug serum concentration for carbamazepine
14056-6 Drug serum concentration for carbamazepine
14639-9 Drug serum concentration for carbamazepine
18270-9 Drug serum concentration for carbamazepine
29147-6 Drug serum concentration for carbamazepine
29148-4 Drug serum concentration for carbamazepine
32058-0 Drug serum concentration for carbamazepine
32852-6 Drug serum concentration for carbamazepine
47097-1 Drug serum concentration for carbamazepine
CPT Description: Drug serum concentration for phenobarbital
80184 Phenobarbital
LOINC Description: Drug serum concentration for phenobarbital
3948-7 Drug serum concentration for phenobarbital
3951-1 Drug serum concentration for phenobarbital
10547-8 Drug serum concentration for phenobarbital
14874-2 Drug serum concentration for phenobarbital
34365-7 Drug serum concentration for phenobarbital
CPT Description: Drug serum concentration for phenytoin
80185 Phenytoin; total
80186 Phenytoin; free
LOINC Description: Drug serum concentration for phenytoin
3968-5 Drug serum concentration for phenytoin
3969-3 Drug serum concentration for phenytoin
14877-5 Drug serum concentration for phenytoin
32109-1 Drug serum concentration for phenytoin
40460-8 Drug serum concentration for phenytoin
CPT Description: Drug serum concentration for valproic acid
80164 Dipropylacetic acid (valproic acid)
LOINC Description: Drug serum concentration for valproic acid
4086-5 Drug serum concentration for valproic acid
4087-3 Drug serum concentration for valproic acid
4088-1 Drug serum concentration for valproic acid
14946-8 Drug serum concentration for valproic acid
18489-5 Drug serum concentration for valproic acid
21590-5 Drug serum concentration for valproic acid
32119-0 Drug serum concentration for valproic acid
32283-4 Drug serum concentration for valproic acid
Medicare denial codes, reason, remark and adjustment codes.Medicare, UHC, BCBS, Medicaid denial codes and insurance appeal. Sample appeal letter for denial claim. CO, PR and OA denial reason codes codes.
Pages
- Home
- Medicare denial code - Full list - Description
- Healthcare policy identification denial list - Most common denial
- Medicare appeal - Most commonly asked questions ?
- TOP 6 CODING ERRORS - Humana
- Medicare No claims/payment information FAQ
- Top Six tips to avoid insurance denial
- How insurance identifying duplicate claim - proces...
- Rejection code 34538, 36428, 39929,76474, c7010 - solution
Thursday, May 4, 2017
Subscribe to:
Post Comments (Atom)
Popular Posts
-
MCR - 835 Denial Code List PR - Patient Responsibility - We could bill the patient for this denial however please make sure that any oth...
-
Locating PLBs • Provider-level adjustments can increase or decrease the transaction payment amount. • Adjustment codes are located in P...
-
BCBS insurance denial codes differ state to state and we could not refer one state denial code to other denial. Here we have list some of th...
-
Claim appeal If you believe you were underpaid by us, the first step in resolving your concern is to submit a Claim Reconsideration as d...
-
PROVIDER ADJ DETAILS The provider-level adjustment details section is used to show adjustments that are not specific to a particular cla...
-
CPT Code and Definitions 36415 Collection of venous blood by venipuncture 36416 Collection of capillary blood specimen (e.g., finger, hee...
-
Medicare contractors are permitted to use the following group codes: CO Contractual Obligation (provider is financially liable); CR Co...
-
CO 97 Payment adjusted because this procedure/service is not paid separately. Explanation: • The benefit for this service ...
-
Medicaid Claim Denial Codes N1 - N50 N1 You may appeal this decision in writing within the required time limits following receipt of...
-
MCR - 835 Denial Code List CO : Contractual Obligations - Denial based on the contract and as per the fee schedule amount. CO should ...
No comments:
Post a Comment